Additional detailed data review and analysis is un

Additional detailed data review and analysis is underway and an end-of-Phase 2 meeting with the FDA will be requested to help determine the dose(s) and design for future studies, which may include higher dosing regimens to determine Prurisol’s maximum therapeutic effect. The Company plans to release other summary findings from this trial in the coming months, with full results anticipated to be submitted for journal publication and presentation at a future medical congress . - See more at: http://cellceutix.com/cellceutix-phase-2-tria...Cow9Q.dpuf